Zobrazeno 1 - 10
of 109
pro vyhledávání: '"M Alfarano"'
Autor:
G Manguso, M Alfarano, F Ballatore, F Ajmone, R Verardo, M Magnocavallo, G Bagnato, P Ciaramella, E Maggio, A Vernile, J Costantino, M Mariani, A Frustaci, C Lavalle, C Vizza, C Chimenti
Publikováno v:
European Heart Journal Supplements. 25:D28-D29
Background In cardiac amyloidosis, the deposition of insoluble amyloid fibrils can affect the cardiac conduction tissue, causing bradyarrhythmic clinical manifestations, often in the advanced stages of the disease. In this clinical case, atrioventric
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::95ae7690332f9ba07c5ec58f03a68068
https://doi.org/10.1093/eurheartjsupp/suad111.066
https://doi.org/10.1093/eurheartjsupp/suad111.066
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
E Maggio, F Ballatore, F Ajmone, G Manguso, R Verardo, P Ciaramella, A Vernile, M Alfarano, C Vizza, C Chimenti
Publikováno v:
European Heart Journal Supplements. 25:D182-D182
Background Properly treated AL cardiac amyloidosis can have a long survival. However, the mechanism involved in arresting or reversing cardiomyopathy, such as toxic suppression of the light chain or removal of the amyloid substance, is still unclear.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c3ae22ebc29416a471c031c369766080
https://doi.org/10.1093/eurheartjsupp/suad111.427
https://doi.org/10.1093/eurheartjsupp/suad111.427
Publikováno v:
European Heart Journal Supplements. 25:D180-D180
Background Hereditary transthyretin amyloidosis (ATTRv) is a rare, adult–onset, autosomal dominant genetic disorder caused by mutations in the TTR gene. The growing availability of effective therapies determining a greater benefit the earlier they
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0189d36a47f5ffbb7d1e58044c415e08
https://doi.org/10.1093/eurheartjsupp/suad111.422
https://doi.org/10.1093/eurheartjsupp/suad111.422
Autor:
F Ballatore, J Costantino, M Alfarano, F Ajmone, G Manguso, E Maggio, P Ciaramella, C Vizza, C Chimenti
Publikováno v:
European Heart Journal Supplements. 25:D188-D188
Background Myopericarditis following vaccination for Sars–CoV2 disease (COVID–19) is a described entity, but its long–term evolution is not yet clear. Methods Patients diagnosed with myopericarditis after COVID–19 mRNA vaccine represented our
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b794e62670c6707bdec8ae9a0ed66440
https://doi.org/10.1093/eurheartjsupp/suad111.440
https://doi.org/10.1093/eurheartjsupp/suad111.440
Autor:
A Vernile, F Ajmone, F Ballatore, E Maggio, G Mancuso, P Ciaramella, C Chimenti, R Velardo, M Alfarano, C Vizza, C Cristina
Publikováno v:
European Heart Journal Supplements. 25:D172-D172
Differential diagnosis of cardiomyopathies with hypertrophic phenotype is crucial because some secondary forms of cardiac hypertrophy can be susceptible of specific treatment aimed to revert and/or stabilize the increase in wall thickness.A positive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::68038d6c0ae31524c668c15b1c3a7d6c
https://doi.org/10.1093/eurheartjsupp/suad111.399
https://doi.org/10.1093/eurheartjsupp/suad111.399
Autor:
F Ajmone, J Costantino, G Manguso, P Ciaramella, F Ballatore, E Maggio, A Vernile, M Alfarano, C Lavalle, C Vizza, C Chimenti
Publikováno v:
European Heart Journal Supplements. 25:D181-D181
Backgound: Cardiac amyloidosis is associated with an increased thromboembolic risk. While the need to anticoagulate patients in atrial fibrillation regardless of the CHA2DS2–VASc score is evident, it is not clear whether and which patients in sinus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9b2dbb287d68bb76992bb086b85bb99d
https://doi.org/10.1093/eurheartjsupp/suad111.424
https://doi.org/10.1093/eurheartjsupp/suad111.424
Autor:
P Ciaramella, F Ajmone, E Maggio, J Costantino, G Manguso, F Ballatore, M Magnocavallo, M Alfarano, C Vizza, C Chimenti
Publikováno v:
European Heart Journal Supplements. 25:D180-D180
Background In the ATTRACT trial, Tafamidis has been shown to be effective in patients with transthyretin amyloidosis (ATTR) by improving quality of life and survival at 30–month follow–up. However, it‘s not clear which are the clinical–instru
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::32973f9296f414f73e22a8bed7cc5eb0
https://doi.org/10.1093/eurheartjsupp/suad111.420
https://doi.org/10.1093/eurheartjsupp/suad111.420
Autor:
C Lavalle, M Magnocavallo, M Mariani, G Vetta, D Della Rocca, M Alfarano, A Piro, A Natale, F Fedele, D Vizza, A Frustaci, C Chimenti
Publikováno v:
European Heart Journal Supplements. 24
Background The diagnosis and management of patients with myocarditis with ventricular arrhythmic (VA) onset is one of the major challenging issues faced by physicians. Objective We aimed at evaluating the natural history of patients with an endomyoca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d6030a64fa69b59079171791f19e4a35
https://doi.org/10.1093/eurheartj/suac011.064
https://doi.org/10.1093/eurheartj/suac011.064